AN2 Therapeutics (ANTX) Income from Continuing Operations (2021 - 2026)
AN2 Therapeutics' (ANTX) quarterly Income from Continuing Operations came in at 17349000.0 in Q1 2026, down 55.71% year-on-year from 39169717.93 in Q1 2025, and down 95.35% on a QoQ basis from 8881000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Income from Continuing Operations data on file, last reported at 17349000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 55.71% year-over-year to 17349000.0 in Q1 2026; TTM through Mar 2026 was 42550000.0, a 59.35% increase from a year earlier, with the FY2025 full-year figure at 35345000.0, up 67.7% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 17349000.0, down from 8881000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ANTX reached as high as 6595000.0 in Q2 2025 and fell as low as 65629000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 22742117.65 across 5 years, with a median of 17349000.0 in 2026.
- Across the five-year window, Income from Continuing Operations tumbled 991.8% in 2022 and surged 86.47% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 11866000.0 in 2022, then plunged by 410.98% to 60633000.0 in 2023, then slipped by 8.24% to 65629000.0 in 2024, then jumped by 86.47% to 8881000.0 in 2025, then tumbled by 95.35% to 17349000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 17349000.0 in Q1 2026, 8881000.0 in Q4 2025, and 9725000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | AN2 Therapeutics | 167.57 Mn | 167.57 Mn | - | -17.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.35 Mn |
| Dec 31, 2025 | -8.88 Mn |
| Sep 30, 2025 | -9.73 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -11.14 Mn |
| Dec 31, 2024 | -65.63 Mn |
| Sep 30, 2024 | -12.92 Mn |
| Jun 30, 2024 | -14.98 Mn |
| Mar 31, 2024 | -17.62 Mn |
| Dec 31, 2023 | -60.63 Mn |
| Sep 30, 2023 | -39.59 Mn |
| Jun 30, 2023 | -21.38 Mn |
| Mar 31, 2023 | -22.34 Mn |
| Dec 31, 2022 | -11.87 Mn |
| Sep 30, 2022 | -30.22 Mn |
| Jun 30, 2022 | -13.39 Mn |
| Mar 31, 2022 | -22.36 Mn |
| Dec 31, 2021 | -13.05 Mn |
| Sep 30, 2021 | -6.91 Mn |
| Jun 30, 2021 | -4.98 Mn |